Coronavirus disease 2019 (COVID-19) is now recognized to be a highly prevalent endemic viral illness, with diabetes associated with increased likelihood of severe infection and mortality. We have reviewed the associations of diabetes with immune response to COVID-19 itself and to the COVID-19 vaccine, as well as discussed the existing evidence of the efficacy of the vaccine in persons with diabetes. Immunity to vaccination appears to decline more rapidly in patients with diabetes than in persons without diabetes, and the existing evidence suggests COVID-19 vaccination to be safe in patients with diabetes, leading us to conclude that patients with diabetes should be prioritized for vaccination and for booster doses.
CITATION STYLE
Nassar, M., Misra, A., & Bloomgarden, Z. (2023). COVID-19 Vaccination in Persons with Diabetes: How they Work. In Contemporary Endocrinology (Vol. Part F636, pp. 195–206). Humana Press Inc. https://doi.org/10.1007/978-3-031-28536-3_13
Mendeley helps you to discover research relevant for your work.